Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Novavax Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.13, while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Novavax Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | NVAX | |
|---|---|---|
52-Week High | $112.91 | $11.19 |
52-Week Low | $105.96 | $6.22 |
Market Cap | — | $1.31B |
Sector | — | Health |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $106.12 with minimal daily movement (+0.15%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts ranging from $0.38 to $0.46 per share. Market focus remains on inflation data and Federal Reserve policy amid ongoing Middle East tensions affecting bond yields.
Investment-grade corporate bond ETFs face headwinds from rising Treasury yields and inflation concerns. LQD's stability in dividend payments provides income appeal, but technical weakness suggests cautious near-term positioning. Key risks include interest rate sensitivity and geopolitical volatility impacting fixed income markets.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
